1 / 28

PRIMA Investigator Meeting

PRIMA Investigator Meeting. Saturday, December 9th, 2006 Orlando – ASH meeting. Agenda. Status of the study Study Update Protocol Amendment CT-scan review Monitoring / Administration / Contracts Questions. PRIMA had became a registration trial.

aspen
Download Presentation

PRIMA Investigator Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. PRIMAInvestigator Meeting Saturday, December 9th, 2006 Orlando – ASH meeting

  2. Agenda • Status of the study • Study Update • Protocol Amendment • CT-scan review • Monitoring / Administration / Contracts • Questions

  3. PRIMA had became a registration trial • Agreement between GELA, Roche and Genentech • First contacts end of May, decision in July • The results will be used for registration filing • in EU, US and rest of the world • New responsabilities: • For the sponsor (GELA) • For the investigators • For the coordinating centers • For monitoring the study • For the partners (Roche, Genentech) • For the DSMC • …

  4. Status on August 2006 Argentina Australia Belgium Brazil China Colombia Croatia Czech republic Denmark Finland France India Israel Mexico Netherlands Peru Portugal Serbia / Montenegro Spain Thailand Turkey United Kingdom Uruguay Venezuela New Zealand . 25 countries were active for recruitment . The 900 registered pts target (2nd amendment, early 2006) - reached on August 11th 2006 . 406 pts at the time of randomization: - 176 maintenance - 163 observation - 67 failed randomization (16.5%)

  5. To become a registration trial • New protocol version (version 4.0, amendment 3) needed with several changes : • Compliance with Health Authorities (EMEA, FDA) requirements (PFS, etc…) • Update statistical hypothesis taking into account the results of the EORTC and GLSG studies (patients number) • Changes in protocol and ICF for new and already registered patients • Approval of the DSMC • August 4th 2006 • Submission to the ethics and health authorities in the lead sponsor country : August 18th • Approval by french authorities september 2006 • Dissemination of new protocol and ICF versions to other countries: • september 18th • Accrual resumed in France on October 9th

  6. Agenda • Status of the study • Study Update • Protocol Amendment • CT-scan review • Monitoring / Administration / Contracts • Questions

  7. Current STATUS • 8 countries received approval to register patients again • 977 patients registered (04/12/06) • 601 patients randomized (04/12/06) • Randomization rate ± 84 % Estimated end of recruitment : March, 2007

  8. PRIMA RECRUITMENT

  9. PRIMA RECRUITMENT

  10. Agenda • Status of the study • Study Update • Protocol Amendment • CT-scan review • Monitoring / Administration / Contracts • Questions

  11. Major Changes – 3rd Amendment(1) • Primary objective : PFS instead of EFS • Increase in the follow-up period : 3 to 5 years • Increase in patients number : 1200 (instead of 900) • Exclusion criteria : patient with any history of hepatitis B or hepatitis B virus infection • Eligibility for randomization : • Patients should have received at least : • 4 R-CHOP + 2R • or 6 R-CVP • or 4 R-FCM • Induction chemotherapy regimen : R-MCP deleted

  12. EORTC 20981: K-M curves for PFSSubgroup analysis according to induction median: 51.9 months median: 23.1 months H.R. 0.54

  13. Major Changes – 3rd Amendment(2) • Additional visits and CT-scan in the 2nd year after the end of maintenance/observation • New ICF for new patients (ICF and information letter version 2.0) • An additional ICF to be signed by patients already registered (ICF and information letter version 2.1) • CT-scan collection and review • Induction Chemotherapy doses required by FDA • Changes in the CRF for new patients, specific additional forms for those already registered

  14. Regulatory Update • Belgium, Croatia, Denmark, Finland, France, Thailand, Venezuela and one site of Australia received approval for 3rd amendment • Before starting recruitment, to be provided to GELARC : • CV of Principal Investigator and Co-investigators in each center • PD 35 form for Inv. And Co-Inv • Page of protocol (v3.2 and 4.0) signed by PI • Approvals (Ethics Committee and Health Authorities) for amendment n°2 and n°3 + regulatory certification document • New Informed consent in local language • After reception of all documents, GELARC will send to the local coordinator the new Registration form

  15. Agenda • Status of the study • Study Update • Protocol Amendment • CT-scan review • Administration / contract • Questions

  16. Agenda • Status of the study • Study Update • Protocol Amendment • CT-scan review • Monitoring / Administration / Contracts • Questions

  17. CRFs FLOW CHART • Baseline part (p1 to 9) => sent to GELARC before randomization • Induction / randomization parts (p10 to 18) => sent as soon as possible after randomization or premature withdrawal • Maintenance part => every 4 visits (with evaluation and toxicity pages), likely after each visit in the near future • Progression, event, death : to be faxed to GELARC and sent as soon as possible • AE and original forms of SAE => sent after each monitoring visit All parts have to be monitored before being sent to the GELARC

  18. CRFs Reception / Monitoring • 638 CRF must should have been registered at the end of induction treatment as today : • 97 % of complete baselines received ! • 53 % of complete induction received - 23 % = incomplete induction part - 24 % = missing induction part • Monitoring frequency will be increased in 2007 : every 8 weeks instead of twice a year. Many thanks for your effort to send the induction treatment before the end of this year !!!

  19. QUERY & DATA MANAGEMENT • CRFs validation • parametered tests + medical review • CRFs are validated as follow : • Baseline + induction treatment • Maintenance (every 4 visits) : increased frequency in the near future • Follow-up / progression / death / AEs (at reception) • Clinical data correction Forms will be sent by GELARC after the validation of each part

  20. QUERY & DATA MANAGEMENT • Clinical data correction Forms will be sent by e-mail to the local coordinator (study group, Roche or other) • Answers must be completed directly on the form by the investigator (do not forget to sign and date form ! ) • One copy must be kept in the CRF • Each completed form has to be faxed to GELARC (ASAP) and original forms have to be sent after the next monitoring visit (with CRF pages)

  21. SAE s (1) • A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution. It is any adverse event that at any dose fulfils at least one of the following criteria: • is fatal (results in death) (note: death is an outcome, not an event) • is life-threatening (note: the term “life-threatening” refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which could hypothetically have caused death had it been more severe) • required patient hospitalization or prolongation of existing hospitalization (note: “inpatient hospitalization” refers to an unplanned, overnight hospitalization) • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • is medically significant or requires intervention to prevent one or other of the outcomes listed above

  22. SAE s (2) • During the induction phase, • all SAEs have to be recorded up to 30 days after the last dose of induction therapy • treatment related SAEs have to be reported at any time beyond 30 days after the last dose of induction therapy. • During the maintenance phase, • all serious adverse events encountered up to 6 months after the last dose of rituximab or last observation visit have to be reported • treatment related SAEs have to be reported at any time beyond 6 months after the last dose of maintenance therapy/last observation visit.

  23. SAE s (3) • All Serious Adverse Events (SAE) must be reported to the respective Group Principal Investigator or Data Manager by fax within 24 hours of the initial observation of the event. • Any adverse event that is considered SERIOUS must be reported within one working day (IMMEDIATELY) by the investigator to the GELARC Safety Desk. • It is a legal requirement to report serious adverse events.

  24. SAEs report and follow-up • Please be precise in the description of the medical event : provide one event, but detail the presence of absence of relevant conditions, specially when the outcome is fatal : • Ex : if pneumonia after chemo: describe blood counts at onset, any microbiology results, etc… ; • Ex : if cardiovascular, describe previous history, treatments, etc… • Please respect the delays (1 day) • Please follow-up the events • Please answer the queries

  25. PRIMA = timelines • according to the assumptions in the protocol the analyses are planned at the following timepoints: • 1st interim analysis (172 events) -  29 months after the first patient has been randomized to maintenance • 2nd interim analysis (258 events) -  37 months after the first patient has been randomized to maintenance • final analysis (344 events) -  46 months after the first patient has been randomized to maintenance • end of study: 5 years after the last patient has finished maintenance therapy - 11/07 - 07/08 - 05/09 - 09/14 !

  26. Administration / Contract • All contracts will be updated : • with Cooperative Groups in EU + Australia/NZ + Brazil + Israel • with Roche Affiliates outside EU (were Roche is the sponsor) • Substantial increase in investigator fee • Paid by GELA to cooperative groups in EU, Au/NZ, Brazil, Israel • Paid by Roche affiliates in Roche sponsor countries • Monitoring Plan + SDV Plan will be attached to the new contract • 1st batch of Investigator’s fees will be paid at the beginning of 2007 (if contract is signed)

  27. PRIMA : a collaborative effort for the largest follicular lymphoma trial

  28. Agenda • Status of the study • Study Update • Protocol Amendment • CT-scan review • Monitoring / Administration / Contracts • Questions

More Related